INTRODUCTION
Computer-generated drug label (CGDL) is the printed material comprising essential drug and patient information and relevant instruction for use to help appropriate and safe use of medication. The design and content of CGDL can impose a significant effect on the way medications should be used. Labels are intended to clearly identify a specific patient and guide him on appropriate use of his medication. [1] Studies have proved that technologies have a role in reducing medication errors. [2] [3] However, technologies may facilitate new medication errors. Researcher Samaranayake and his colleagues evaluate the role of computerized physician order entry systems (CPOE) on 1538 medication incidents and reported that 17.1% of all incidents were technology-related, where 6.8% were related to computer-aided drug label generation. The direct causes for technology associated errors included user-PC poor interface (68.1%), rule violations (22.1%), technical defects (1.9%) and others. Also, they reported that 11.4% of technology-related incidents were detected after drug administered and 6.1% of them actually caused harm to patient. [4] Walsh et al. using a newer version of the same CPOE system, found only 4 types of errors. [5] Koppel et al. conducted a large study to assess the correlation between technology and medication errors and found few instances where errors can occur despite of technology, demonstrating that errors may have been eliminated by excellence in technology. [6] However, unintended medication errors still occur despite improvements in technology. It is quite possible that newer technologies will come up with new types of CGDLEs; therefore, technology-related errors must be evaluated on regular basis.
The culture of safety is promoted among all Omani public hospitals and as a strategy to improve quality of patient care, the Hospital Information System (HIS) in the royal hospital has been used to manage the CGDLs as part of medication dispensing process. A bilingual (English + Arabic) label generated by this system usually contains patient's particulars, medication name, dosage form, strength, dose, frequency, duration and cautionary instructions, if any.
MATERIALS AND METHODS Setting
This study was undertaken in the Pharmacy Department of the Royal Hospital, a government-funded tertiary care, 500 beds, public hospital in Oman. The hospital information management system (HIMS) was introduced in this hospital in 2007 and pharmacists have been using this system to facilitate prescription screening and medication dispensing processes, including computer-generated drug labels. We define Computer-generated drug label error (CGDLE) as any error related to a computer-generated label used in the medication dispensing process. On average, 400 prescriptions were received from different departments/clinics daily including inpatient discharge prescriptions.
medications include Budesonide+ formoterol (21.87%), in addition to ciclosporin capsule, dornase for inhalation and thyroxine tablets. As we can see in Table 4 , most of the medications associated with CGDLEs were under the class of immunosuppressants and/or cytotoxics. This may indicate the seriousness of such errors as most, if not all of these medications could impose a potential life threating adverse effect on patients, especially pediatric and geriatric groups.
Ninety five percent of the identified CGDLEs were captured in station B where items are prepared and labeled. The rest was captured in station C during delivery of medication to the patient. The mean time taken to correct an error was 1.68 minutes (M+SD=1.68+1.23) and the maximum time was 9 min.
DISCUSSION
We assessed the pattern, content and clinical significance of 292 computergenerated drug label errors (CGDLEs) involving 61 medications and 169 patients in a tertiary care hospital. Thirty eight percent of the detected GCDLEs were considered as major errors. Shrank et al. found that medication labels poorly designed accounted for approximately 33% of errors investigated by the US Pharmacopoeia and in many cases, it was due to confusion caused by the label. [9] Furthermore, it is common that patients may receive no verbal instructions from healthcare providers except the instructions on the label and this highlights the importance of the welldesigned medication label. [10] Labeling improvements guidelines have been presented in two recent Institute of Medicine (IOM) reports focusing on medication safety. According to IOM reports, poor labeling is an important source of medication/dispensing errors and variability in drug labeling can negatively affect a patient's comprehension of instructions. [11] [12] In our study female gender represented 71.6% of the study population. The age of patients ranged between 0.2 to 97 years (M+SD=36.4+24.3) ( Table 2 ). Recode of patient age stratified by level of clinical significance of error shows that errors affecting this age group represented 7.89% of the total errors. Out of this 1.37% were considered major. Eerrors affecting age group above 60 years of age represented 21.91% with 8.90% of them considered as major errors (Table 3) . Table 4 shows medications commonly affected by CGDLEs stratified by the level of clinical significance of error. Errors classified to be major represented 38.69% of the total errors and commonly associated with immunosuppressants (tacrolimus capsule and Ciclosporin capsule) and cytotoxics/anti-rheumatics (Methotrexate injection/tablet). Errors considered as moderate represented 28.77% and commonly associated using data collection form (DCF). The contents of the DCF included patient demographics, type of error, error-related medication, time taken to resolve the error, station where error was discovered and the clinical significance of the error. The study was approved by the University of Nizwa research committee and the Royal Hospital authorities.
Error review and classification
The CGDLEs were reviewed and classified by a panel of three senior clinical pharmacists. The clinical significance of error was defined as major, moderate, mild and none after a previously described method for risk matrix definitions and their impact on patients. [7] (Table 1) The panel assessed the potential for patient harm of each error. As per Nanji et al. potential error was considered major if the event could cause symptoms that lead to patient death if not treated; examples include patient fatality or potential end organ damage, cardiac arrest, anaphylaxis and respiratory failure. A potential error was considered moderate if the event could cause symptoms that are associated with a serious but non-life-threatening level of risk; example include harm that needs hospitalization or emergency treatment, symptomatic bradycardia, dizziness and syncope. A potential error was termed mild if the event could cause symptoms that, while harmful to the patient, pose little or no threat to the patient's life function; example include that does not need hospitalization or emergency treatment like rash, mild diarrhea, nausea and headache. In the 'none' class, there is error but no obvious harm to the patient. [8] Outcomes Our primary outcomes were the incidence of computer-generated drug label errors and the related potential for patient harm. Our secondary outcome was the rate of CGLEs by error pattern. Error patterns included drug dose, frequency, duration, dosage form and patient instruction for use.
Data analysis
Statistical analyses were conducted using STATA version 14.2 (Stata Corporation, 2015; College Station, TX, USA). For continuous variables, means and standard deviations were reported. For categorical variables, frequencies and percentages were reported. We applied Chi-square tests to examine bivariate associations between errors and recoded age groups. Medications commonly associated with potential CGDLEs were presented as counts with percentages.
RESULTS
The age of patients affected by CGDLs ranged between 0.2 to 97 years (M+SD=36.4+24.3). Errors within the age group of 0.2 to 2 years represented 7.89% of the total errors where 1.37% of them considered major. Errors affecting the age group of 61 years and above represented 21.91% of the total errors where 8.90% of these errors considered major. Figure 1 shows the patterns of CGDLEs (duration of therapy, Instructions for use, drug dose, frequency of drug doe, etc) and the commonly involved medications in each pattern where duration of therapy represented 34.59% and commonly involved medications include methotrexate injection/tablets (36.63%), adalimumab injection, erythropoietin injection and etanercept injection. Instructions for use comprised 29.45% of the errors and include medications like adalimumab injection (18.60%), methotrexate injection/ tablet, ciclosporin capsule and syrup, tacrolimus capsule, erythropoietin injection and sodium 0.9% injection. Errors affecting drug dose represented 19.86% of the total errors and the commonly involved medications include ciclosporin capsule and tacrolimus capsule (12.06% each). The frequency of drug dose errors represented 10.96% and the commonly involved with asthma medications (budesonide + formoterol) and antimicrobials (cotrimoxazole tab/suspension). The minor level of clinical significance represented 25.00% and commonly associated folic acid tablet and vitamin D3 capsule.
We identified medications like erythropoietin injection, sodium chloride injection and pancreatic granule were commonly associated with the major errors involving age group < 2years, while medication like tacrolimus capsule, etanercept injection and ciclosporin capsule were commonly associated with the major errors involving age group of > 60 years of age. Sergey Zakharov et al. studied the types and reasons arising from medication errors in general, for 11 years. They found that 60.46% of errors involved children below 5 years of age. The most frequent medication errors involved medications affecting the nervous system (psycho-leptics and anti-epileptics), antibiotics and medications affecting the respiratory system specially in patients over 60 years of age. They concluded that there are two high risk categories, children < 5 years of age and geriatrics with chronic medications, therefore, risk reduction measures should focus primarily on these two categories. [13] CGDLEs associated with instructions for use comprised 29.45% of the total errors and included medications like adalimumab injection, methotrexate injection, ciclosporin capsule and syrup, tacrolimus capsule, erythropoietin injection and sodium 0.9% injection. Davis et al in their cross-sectional survey involving 251 primary care patients studied the comprehension of drug label by patients and reported that slightly more than half of patients misinterpreted common instructions. [14] Errors associated with drug dose in this study represented 19.86% of the total errors and commonly associated with medications like ciclosporin capsule and tacrolimus capsule. The frequency of drug use errors comprised 10.96% and commonly associated with budesonide + formoterol for inhalation, ciclosporin capsule/solution, dornase for inhalation and thyroxine tablets. The duration of therapy errors comprised 34.59% of the total errors and commonly associated with medications like methotrexate tablets, adalimumab injection, erythropoietin injection and etanercept injection.
Yin et al. studied comprehension of label instructions on 287 parents or caregivers of children prescribed a liquid medication. They concluded that parents using teaspoons or tablespoons to measure the dose were more likely to make errors compared with those who used milliliter-based instruments. [15] Another study by Davis et al. found that only 71% of educated consumers can interpret the statements 'take two tablets twice daily' correctly. Clear statements such as 'take two tablets in the morning and take two tablets in the evening' can ease the understanding of the instructions. Confusing instructions such as 'use as directed' are not preferred and should not be used unless accompanied with the maximum frequency per day. [16] Our labels are printed in English with Arabic translation, as Arabic is the mother language of most of our patients. Therefore, errors may occur due to inappropriate translation. Translation researchers and practitioners agree that effective translation needs more than just replacing each word in English text with a similar word in another language. Therefore, translators should accurately evaluate the intended purpose of the original English text and determine how the same purpose can be conveyed in another language. [17] [18] Our results show that 95.27% of the identified CGDLEs were captured and corrected in station B where picking of medication and sticking of computer-generated label is done; the rest was captured in station C during delivery of medication to patients. Fortunately, all these errors were captured before reaching patients. We believe the reason behind that is the application of safety culture in the department including counterchecking. The Mean time taken to correct an error was 1.68 min (M+SD=1.68+1.23) and the maximum time taken for error correction was 9 minutes. After identifying the error, the pharmacist manually does the correction in English and Arabic before delivering medication to the patient. The ccorrection is done by using a new hand-written label in place of the erratic one. Verbal instructions were also conveyed to the patient to confirm the correction.
Our study showed that CGGLs could represent a source of considerable errors where some of these errors could be life-threatening. The nature of these errors may include mix-up between drug format, inappropriate use of metric units (dosing instruction was in mg rather than milliliter), wrong or missing frequencies and duration mismatch between English and Arabic instructions. The following case reports may illustrate some examples of computer-generated drug label errors detected in in our study:
Case 1:
A 50-year-old man, post total thyroidectomy prescribed thyroxin tablets as 75 microgram 2 timed daily for 90 days. The drug was dispensed as tablets of 25 micrograms. The label says "take 3 tablets daily for 30 days". The Arabic translation says the same.
Case 2:
A 4-year-old child with cystic fibrosis prescribed dornase (1mg/ ml) for inhalation. The dose was 1.5 mg once daily. The label says "inhale 1½ mg once daily". No further instruction on how to administer the drug and for how long. No Arabic translation.
Case 3:
A 7-year-old child with asthma prescribed sodium chloride 0.9% ampule to be added to budesonide in the nebulizer twice daily. The label says "inject 3 ml twice daily". No more instructions for use. Arabic translation says the same.
Case 4:
A 48-year-old lady with renal transplantation prescribed ciclosporin (among other 12 medications) in split dose as 75 mg morning and 50 mg evening. The label says "take 75 mg in the morning". The evening dose is missing. Arabic translation says the same.
Case 5:
A 47-year-old patient with rheumatoid arthritis was prescribed adalimumab as 40 mg to be injected once every 2 weeks for 12 weeks. The label says "inject 40 mg weekly for 4 days". Arabic translation says the same.
Case 6:
A 34-year-old patient, post renal transplantation, was prescribed darbepoetin alfa injection as 40 microgram per week for 5 weeks. The label says' inject 40 microgram every week for 1 week". Arabic translation says "inject 40 microgram every week for 1 day".
Case 7:
A 4-year-old child prescribed tacrolimus syrup, 1.5 ml twice daily (to be adjusted according to the drug level in the blood) for 90 days. The label says "take 1½ ml twice daily for 31 days". Arabic translation says the same. No instructions about drug monitoring in the label.
Case 8:
A 10-year-old child with asthma was prescribed tiotropium rotacapsule as 18 microgram to be inhaled once daily. The label says "inhale 18 microgram daily in English and Arabic. No instruction for use.
Case 9:
A 5-year-old child was prescribed hydrocortisone cream 0.1% to be applied sparingly twice daily for one Week. The instructions in English and Arabic on the label says "apply 1% twice daily" and no duration stated. Optimal patient outcomes could be provided only if instructions on the drug label used as intended. This may highlight the importance of drug labels in ensuring safe and effective use of prescription and non-prescription medications. If the patient is unable to identify his medication or understand the instructions for use printed on the label, the effort made in developing the label is useless. Pharmacists and IT experts are challenged to work together to ensure that computer-generated labels prevent harm to patients while supporting the quality use of medications. Staff training and system monitoring are also required to minimize technology-related medication errors.
Limitations
In fact, we focused only on direct causes of computer-generated drug label errors and we didn't perform a root cause analysis of these errors or evaluate the possible faults in the system, hence, there may be other causes of in addition to those explained in this study. Also, this study was done in one hospital and therefore, findings may not be generalized. Finally, our findings should be interpreted carefully as they were based only on the identified and captured errors.
CONCLUSION
A clinically significant amount of computer-generated drug label errors was observed. Most of these errors were serious and can directly affect the wellbeing of patients. Fortunately, these potential errors were captured before reaching the patient. Critical evaluation and correction of the system Figure 1 : Patterns of computer-generated drug label errors (N=292).
that generates such labels is required. These findings emphasize the need to further assess how to best communicate drug-related information to patients using a well-designed computer-generated drug labels.
